In a bold, controversial, and potentially paradigm-shifting move, the state of Montana has officially greenlit a framework that positions it as a pioneer in the American "right-to-try" landscape. Under new regulations finalized this week, biotechnology firms developing drugs—many of which have only undergone rudimentary testing in small cohorts of healthy adults—can now bypass traditional federal oversight to offer experimental treatments directly to the public.
For the biotech industry and proponents of the longevity movement, this represents a liberation from the bureaucratic bottlenecks of the FDA. For medical ethicists and patient safety advocates, however, it is a perilous descent into an era of unregulated human experimentation.
The Regulatory Framework: A Pay-to-Play Medical Frontier
The core of Montana’s new legislation rests on a streamlined, state-sanctioned approval process. Biotech companies are now permitted to pay a $12,500 application fee to a newly formed, state-established review board. Upon receiving the board’s "rubber stamp," these companies can authorize the sale of their unproven therapies via specialized experimental treatment clinics. The first of these facilities is expected to be operational by the end of 2026.
This model is distinct from existing federal right-to-try laws, which typically require a higher threshold of evidence and are generally restricted to patients with terminal illnesses. Montana’s approach is far more permissive: theoretically, any individual who provides informed consent and possesses the financial means to pay can access these therapies.
A Chronology of the Montana Experiment
The trajectory toward this "experimental hub" status did not occur in a vacuum. It is the culmination of years of lobbying and a shifting cultural perspective on medical autonomy.
- Pre-2023: Growing frustration among the longevity and rare-disease communities regarding the "valley of death"—the period where drugs show promise in preclinical trials but remain years away from full regulatory approval.
- March 2023: The birth of Brody DeVault, whose condition, creatine transporter deficiency, would later become a focal point for the necessity of this legislation.
- Late 2025 – Early 2026: Legislative sessions in Montana saw intense debate between state lawmakers, who framed the issue as one of personal liberty, and medical associations concerned about the erosion of the scientific method.
- July 2026: The state officially opens the application process for the new medical review board, effectively launching the experimental hub program.
- Late 2026 (Projected): The opening of the state’s first authorized experimental treatment clinics.
The Human Cost: The Case of Brody DeVault
The political rhetoric surrounding this legislation is often overshadowed by the stark reality of parents like Kris DeVault. His son, Brody, suffers from a rare, debilitating condition that prevents his brain and muscles from processing energy effectively. Currently, there is no medical cure for his diagnosis.
DeVault’s situation highlights the primary driver of this legislation: desperation. He has identified a pharmaceutical candidate currently in early-stage development. While the drug has shown potential in animal models and a microscopic number of healthy humans, it remains barred from clinical use. For DeVault, the risk of side effects or failure is secondary to the lack of any alternative. "We are out of time," supporters argue. "To deny a parent the right to choose an experimental path is to deny them hope."
Supporting Data and the "Valley of Death"
The biotech industry often cites the immense costs and timeframes required for FDA approval as a barrier to innovation. On average, bringing a new drug to market takes over a decade and billions of dollars. Proponents of the Montana model argue that by creating a sandbox for early-stage testing, the state can:
- Accelerate Data Collection: Real-world usage, even if unregulated, provides data points that might otherwise take years to gather.
- Attract Investment: By lowering the barrier to entry, Montana aims to position itself as a magnet for boutique biotech firms that currently struggle to survive the early phases of clinical development.
- Address Rare Diseases: Diseases that affect small populations are often ignored by big pharma due to low ROI. This model could create a marketplace where these treatments become economically viable sooner.
The Dangers of Unchecked Innovation
Critics, however, point to the potential for "medical tourism" of the most dangerous kind. The primary concerns include:
- Informed Consent Validity: Critics argue that "informed consent" is a myth when a patient is desperate and the company providing the drug has a financial incentive to sell it. Can a patient truly weigh the risks of an unproven compound when they are searching for a miracle?
- The "Snake Oil" Problem: Without rigorous oversight, there is a high risk that the state could become a hub for fraudulent therapies. History is littered with examples of "miracle cures" that caused significant harm before being debunked.
- Erosion of Trust: If early, high-profile cases result in severe adverse events or deaths, it could set back the legitimate, science-based biotech industry by decades, leading to a public backlash against all medical innovation.
The Need for a New "Office of Technology Assessment"
The current climate of rapid, high-stakes technological advancement—from gene editing and experimental pharmacology to the unchecked growth of AI—has led many to suggest that we are flying blind. There is a renewed, urgent call for the reinstatement of the US Office of Technology Assessment (OTA).
The OTA, which served Congress from 1972 to 1995, acted as a "truth-telling" arm of the government. Its 750+ reports provided Congress with objective, non-partisan analysis of emerging technologies. In an era where Montana is gambling on experimental medicine and Big Tech is rushing to deploy AI models that have already shown the capacity to "hack" external systems, the absence of such an institution is glaring.
The OTA’s role was to distinguish between genuine scientific advancement and mere technological "snake oil." As we see in the current AI landscape—where investment is soaring to $1.5 trillion while companies grapple with "catastrophically expensive" cost overruns—the lack of independent oversight has led to a volatility that affects everyone from the average worker to the global economy.
Broader Implications: A Shifting Global Paradigm
Montana’s move is not an isolated event; it is part of a global struggle to define the role of the state in the era of radical innovation. As Europe braces for climate-driven disasters and the international community struggles with the implications of drone warfare and sovereign AI, the question remains: who is the arbiter of safety?
Whether it is the "right to try" a new drug or the deployment of an autonomous system, the tension between the freedom to innovate and the duty to protect the public is at an all-time high.
Conclusion: The Path Forward
As we look toward the end of 2026, the world will be watching Montana. If the state’s clinics successfully provide life-saving treatments to patients who had no other options, it could lead to a massive overhaul of how the US handles medical testing. If, however, the project results in a public health crisis or a series of preventable tragedies, Montana may serve as a cautionary tale for the dangers of abandoning the guardrails of science.
The fundamental tension between the desperate search for a cure and the cold, protective nature of regulatory science has never been more visible. For now, the "Montana Experiment" is no longer just a legislative proposal; it is a live, high-stakes test of the limits of human autonomy and the necessity of state-enforced protection. The results, as always, will be written in the lives of the patients who step through the doors of these clinics.
Quick Look: The Week in Tech
- AI Security: Anthropic joins OpenAI in reporting that their models successfully breached external organizations during testing, signaling a new, dangerous phase in AI capability.
- Climate Change: Europe is bracing for a "fiery future," with experts noting that current heatwaves are mirroring the conditions seen in California, exacerbated by El Niño.
- The AI Spending Spree: Amazon, Google, Meta, and Microsoft are pouring $1.5 trillion into infrastructure, prompting questions about the sustainability of the current AI bubble.
- Digital Governance: LinkedIn has introduced a button for users to report "AI slop," highlighting a growing consumer rebellion against the influx of low-quality, AI-generated content.
